

Endocrine Myopathies: Clinical Review

Hasan H Yeter*

Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey

Abstract

Endocrinopathy is generally associated with hormonally-mediated systemic disorders. Myopathy is a result of this association and sometimes can be the first manifestation of endocrine diseases. This condition generally misdiagnosed as weakness and diagnosis and treatment of endocrine diseases are delayed. Especially cushing's disease, exogen glucocorticoid use, hypothyroidism, hyperaldosteronism and osteomalacia can mimic inflammatory myopathies clinically. Endocrine myopathies are group of disease which must be part of differential diagnosis who has proximal muscle weakness. Statin and glucocorticoid use come to the knowledge of physician because these are the most common cause of drug related proximal myopathy. While evaluating patient with proximal myopathy, thyroid function tests, vitamin D levels, parathyroid hormone must be measured and primary hyperaldosteronism work up when clinically suspicion occurs. Treatment of endocrine myopathies are based on correction of endocrine disorder.

Keywords: Proximal myopathy; Vitamin D; Statin; Cushing's disease; Parathyroid hormone; Primary hyperaldosteronism

Introduction

Myopathy literally means muscle disease. Pattern of weakness in myopathy most commonly involve proximal upper and/or lower limb muscles symmetrically. Myopathy can also, less commonly, involve distal limb, neck, facial, ocular, pharyngeal, respiratory and cardiac muscles. There is a broad range of underlying causes including drugs, alcohol, endocrine disease, Idiopathic Inflammatory Myopathies [IIM], hereditary myopathies, malignancy, infections and sarcoidosis [1] (Table 1). Patient's medical and family history, severity of symptoms, beginning time of symptoms, other endocrine indicators such as weight loss, tachycardia, hair loss, muscle tenderness, stria and cushingoid features must be examined. Patients with non-neurological conditions, such as anaemia, depression or chronic infective and inflammatory illnesses can use the term 'weakness' to describe their fatigue [2]. The following features should help to differentiate fatigue from weakness. Patients with fatigue would describe generalised and non-specific difficulty in performing different tasks that becomes more pronounced as they continue to perform the activity [2]. Some simple bedside tests, such as difficulty of the patient in rising from a low chair with arms folded across the chest or combing her hair could be separate weakness from fatigue. Also proximal myopathy get involved in neurological diseases such as Guillain-Barré syndrome, Myasthenia gravis, Motor neuropathies and Motor neuron diseases [3]. Neurological disorders' clinical presentations are not only muscle weakness and fatigability but also double vision, drooping of eyelids and muscle fasciculations [3]. In the presence of these features would suggest alternative diagnosis. Some of genetic disorders can be with myopathy and endocrinopathy such as Hoffman syndrome and Kocher-Debre-Semelaigne syndrome. On the other hand Myotonic dystrophies, Curschmann-Steinert disease and proximal myotonic myopathy [PROMM], are associated with primary hypogonadism and insulin hypersecretion [4]. While evaluating patient with proximal muscle weakness endocrine diseases such as cushing's disease, thyroid dysfunction, parathyroid dysfunction, primary hyperaldosteronism and osteomalacia must be excluded. Patients with hypothyroidism have muscle symptoms frequently and proximal muscle weakness occurs in about one-third of them. On the other hand, myopathy related with hyperthyroidism occur 62% of patients. Although myopathy due to hypocalcemia is rare, it's association with hypercalcemia is common and due to a retrospective study with fifty one symptomatic hyperparathyroid patient proximal myopathy was the commonest presentation [24/51]. A prospective study of Sharma et al., 37 patients who were diagnosed with endocrine myopathies, thyroid dysfunction was the most common cause [17

cases], followed by vitamin D deficiency in nine, adrenal dysfunction in six, parathyroid dysfunction in three, and pituitary dysfunction in two [5]. While myopathy due to hypothyroidism, hypoparathyroidism, hyperaldosteronism and statin use can cause serum creatin kinase elevation, hyperthyroidism, hyperparathyroidism and glucocorticoids can not. Statin use, hypo-hyperthyroidism, hyperparathyroidism and hyperaldosteronism can also present polymyositis like syndrome. Treatment of myopathy associated with endocrine diseases are based on correction of endocrine disorder (Table 2). In this condition there is no need additional investigation such as muscle biopsy, electrophysiologic studies or genetic tests.

Statin Myopathy

The most common muscle-related adverse event resulting from statin use is myalgia. It's incidence reported in randomized controlled

Endocrine myopathies	Hypothyroidism, Hyperthyroidism Hyperparathyroidism, Hypoparathyroidism, Pituitary Dysfunction, Osteomalacia, Primary Hyperaldosteronism
inflammatory myopathies	polymyositis, dermatomyositis and inclusion body myositis, Vasculitis, lupus, scleroderma, rheumatoid arthritis, Sjögren's syndrome
Hereditary or congenital myopathies	limb girdle, facioscapulohumeral and Becker muscular dystrophy, proximal myotonic myopathy, glycogen and lipid storage disorders
Infections	HIV infection, influenza, hepatitis B and C, enteroviruses, trichinosis, cysticercosis, lyme myositis, epstein barr virus
Toxic myopathies	statins, fibrates, corticosteroids, colchicine, antimalarial drugs, zidovudine, alcohol
Electrolyte disorders	Hypokalemia, Hypophosphatemia, Hypocalcemia, Hyponatremia or hyponatremia

Table 1: Causes of proximal myopathy.

*Corresponding author: Hasan H Yeter, Department of Internal Medicine, Hacettepe University Medical School, Turkey, Tel: +905542397449; E-mail: hasanyeter@hotmail.com

Received April 30, 2015; Accepted May 22, 2015; Published June 04, 2015

Citation: Yeter HH (2015) Endocrine Myopathies: Clinical Review. Endocrinol Metab Synd 4: 178. doi:10.4172/2161-1017.1000178

Copyright: © 2015 Yeter HH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

	Serum CK Elevation	Polymyositis like syndrome	Treatment
Statin Myopathy	+	Yes	Stop treatment. After normalization of serum CK use alternative statin with lower dose or use ezetimib
Glucocorticoids	-	No	If endogen reasons treatment of endocrine disease. If exogenous reason if possible dose reduction
Hypothyroidism	++	Yes	Treatment of underlying disease
Hyperthyroidism	-	Yes	Treatment of underlying disease
Thyrotoxicosis	-	Yes	Treatment of underlying disease and beta-adrenergic blockade with propranolol
	Except thyrotoxic crisis		
Hyperparathyroidism	+	Yes	Treatment of underlying disease
Hypoparathyroidism	++	Yes	Treatment with calcium and calcitriol
Pituitary Dysfunction	++	No	Treatment of underlying disease
Osteomalacia	++	No	Treatment of underlying disease
Primary Hyperaldosteronism	++	Yes	Serum potassium normalization and treatment of underlying disease

Table 2: Endocrine disorders associated with myopathy.

trials ranging from 1.5% to 3.0% [6]. According to one large population-based cohort study the incidence rate of myopathy in lipid-lowering drugs was 2.3 per 10,000 person-years [7]. Risk of myopathy depends on dose [high dose>low dose] and preparation used. In other classification lipophilic statins such as simvastatin, atorvastatin and lovastatin are more likely to produce muscular effects than hydrophilic statins such as pravastatin, rosuvastatin and fluvastatin [8]. Muscle toxicity is more common when statins are combine with other drugs which inhibit Cytochrome P450 3A4 Isoenzyme [CYP3A4] like fibrates, macrolide group antibiotics and amiodarone. On the other hand, simvastatin, atorvastatin and lovastatin are metabolized by the hepatic [CYP3A4] enzyme system but pravastatin, rosuvastatin and fluvastatin do not dependent on CYP3A4 [7]. Other risk factors include older age, liver or renal disease, hypothyroidism, alcoholism and heavy exercise [2]. A retrospective study performed by Smith et al. did not find routine monitoring of Creatin Kinase [CK] for patients on statin therapy helpful [9]. It is unclear but incidence of asymptomatic serum CK elevation approximately %5 and such elevations are not important if the patients are asymptomatic and their CK elevation is less than 10 times normal serum value. If Myalgia occurs with or without CK elevation, myalgia usually improves after discontinuation of the drug but If the muscle strength is normal and the myalgia is tolerable, you can switch statin therapy another preparation [10]. A retrospective study of Hansen et al. reported that resolution of muscle symptoms after a mean duration of 2.3 months following discontinuation of statin [11]. Once symptoms resolve, patients could be rechallenged with lower dose of the same statin or an alternative one like pravastatin or fluvastatin. If muscle symptoms and elevation of CK persist despite stopping statin, muscle biopsy is recommended to exclude alternative diagnoses. However, cases of statin-induced polymyositis and dermatomyositis like syndromes have been reported and such patients require immunotherapy with steroids or IVIg [10]. Non-statin treatment is an option for those with recurrent muscle symptoms despite the lower doses or change the preparation. The National Institute for Health and Clinical Excellence [NICE] recommends ezetimibe for those who would otherwise be started on a statin, but are intolerant.

Glucocorticoids

Glucocorticoid [GC] use as medical treatment is the most common reason of drug related myopathy and steroid myopathy [12]. On the other hand, Cushing's Disease [CD] is the most common cause of

endogenous hypercortisolism. CD is most commonly due to production of ACTH from a pituitary adenoma with an incidence of 39 cases per million population and is more frequent in women than in men with a gender ratio of 15:1[13]. Although acne, muscle weakness, truncal obesity and buffalo hump are common sign of CD, striae[>1 cm wide], facial plethora and proximal myopathy are the spesific clinical features of disease [14]. Dexamethazone and Triamsinolone are the most risky but oral, inhaler and topical steroid use can cause myopathy [15-17]. Endogen and exogen GC myopathy pathway are same. Muscles are effected directly by GC's anti-anabolic and catabolic effects on muscles [18]. GC's decrease the rate of protein synthesis and increase the rate of protein breakdown [19]. They inhibit the stimulatory action of insulin and aminoacids and interrupt IGF-1 signals which play a key role in the protein synthesis [20]. Also GC activate the major cellular proteolytic systems such as the ubiquitin proteasome system, the lyso-somal system and the calcium-dependent systems [19]. Steroid myopathy has a typical pattern of muscle weakness affecting the lower limbs more than the upper limbs and the proximal part of a limb more than the distal part. Typically myalgia and muscle tenderness don't occur [21]. Myopathy risk rises dose and time relatively. There is wide variability in the time course of symptom onset from a few weeks to many months after therapy. Despite this variability, there is a general dose relationship with systemic glucocorticoid therapy. Glucocorticoid myopathy is unusual in patients treated with less than 10 mg/day prednisolone or its equivalent [22]. The higher the dose of glucocorticoid, the greater is the likelihood of developing myopathy and the more rapid is the onset of weakness [22]. There is no definitive diagnostic test for glucocorticoid myopathy [23]. Muscle enzymes are generally normal, there is no electromyography finding but may show low amplitude motor unit potentials and muscle biopsy has no signs of necrosis or inflammation [24]. GC use as treatment of inflammatory diseases such as myopathies conflict with reason of muscle weakness. The onset of weakness or deterioration of clinical features one or more months after glucocorticoid therapy, the presence of other cushingoid features and normal or decreasing serum muscle enzyme levels all indicate glucocorticoid myopathy. Marco A Minetto et al. published a clinical study at 2011 is about diferential diagnosis steroid myopathy and inflamatory myopathies. In conclusion of study, muscle fiber conduction slowing and decreased levels of circulating muscle proteins such as CK and myoglobin can be sensitive markers of steroid myopathy [21]. Treatment of steroid myopathy is disease spesific. If the reason is

ACTH independent adrenal adenoma the patient should be treated by unilateral adrenalectomy [14]. In cases of bilateral hyperplasia, bilateral adrenalectomy may be an option but this choice will result in adrenal insufficiency and require lifetime hormone replacement therapy with glucocorticoids and mineralocorticoids. Unilateral adrenalectomy of the largest gland has been recently proposed as a possible therapeutic alternative for patients [25]. Transsphenoidal adenomectomy is the choice for the most patients with Cushing's disease [26]. Myopathy related Exogenous GC use treatment is if disease allow reduce the GC dose. Symptoms will improve within three or four weeks after reduce GC dose.

Thyroid Function Disorders

A) Hypothyroidism

The most common cause of primary hypothyroidism in the United States is autoimmunity [Hashimoto thyroiditis] [27]. Although myopathy is a rare musculoskeletal manifestation of hypothyroidism muscle symptoms may manifest in 25% to 79% of adult patients with hypothyroidism [28]. These symptoms include pain, cramps, stiffness, easy fatigability and weakness. There are two syndromes which are associated with hypothyroidism and myopathy.

Hoffman syndrome is a rare disease with hypothyroid myopathy and increased muscle mass [pseudohypertrophy] and Kocher-Debre-Semelaigne syndrome is associated with cretinism and muscular pseudohypertrophy [27,29]. Hypothyroidism may present with isolated muscle weakness so it is useful to check thyroid function in all patients with proximal myopathy, even if the absence of other symptoms of thyroid disease. Physical examination findings may include muscle hypertrophy, proximal muscle weakness and delayed relaxation phase of deep tendon reflexes [27,29]. Serum muscle enzyme levels are frequently elevated in patients with hypothyroid myopathy and rise of muscle enzyme is typically mild [CK<1000 IU/L] but polymyositis-like illness or rhabdomyolysis with dramatic elevations in CK levels do exist in the literature [30,31]. There is a correlation between CK levels and thyrotropin-stimulating hormone [TSH] levels but not with a degree of weakness [27,29]. Diagnosis may be supported by Electromyography [EMG], which is often normal but helps in distinguishing hypothyroid myopathy from other myopathies. On muscle biopsy, there is characteristic atrophy of type II muscle fibers, with relative hypertrophy in type I muscle fibers. Other nonspecific finding is internalized nuclei [32]. In most cases of hypothyroid myopathy, symptoms resolve within approximately 6 months of therapy with supplemental thyroxine [27,28,30].

B) Hyperthyroidism

Causes of hyperthyroidism are autoimmunity, infection, drug-induced or iatrogenic. The most common cause of hyperthyroidism is Graves disease worldwide [27]. Altered bone metabolism, pretibial myxedema and rarely myopathy are musculoskeletal manifestations of hyperthyroidism. Hyperthyroid myopathy has a similar presentation as hypothyroid myopathy with proximal muscle weakness manifesting early in the disease course in up to 62% of patients in one study [33]. Neuromuscular symptoms and clinical weakness correlated with free thyroxine [T4] concentrations [28,34]. In contrast with hypothyroidism, serum CK levels are typically normal and myopathic findings on EMG were rare [28]. In the literature most of studies sustain myopathy associated hyperthyroidism, some of them come out with weakness is a functional muscle disorder rather than myopathy [28]. Symptoms of weakness resolve within the therapy for hyperthyroidism [28,34,35].

C) Thyrotoxicosis

Younger patients generally have sympatho-adrenergic symptoms and thyrotoxic myopathy is a rare clinical finding such as rhabdomyolysis and hypokalemic periodic paralysis [36]. Chronic thyrotoxicosis may affect bulbar muscles and can be fatal [37,38]. Bulbar myopathy develops in 16.4 percent of patients with chronic thyrotoxic myopathy [37]. Other clinical fatal syndrome is Thyrotoxic Periodic Paralysis [TPP] [39]. TPP is a form of secondary hypokalaemic periodic paralysis and generally affect in the age group of 20-40 years male [40]. Chronic thyrotoxic myopathy is more common. About two-thirds of patients with hyperthyroid myopathy report proximal weakness that usually begins several weeks to several months after the onset of hyperthyroidism which is common in men then women [41]. Serum CK is generally normal, except in thyrotoxic crisis, but elevated aldolase occurs in approximately 30 percent of patients. Beta-adrenergic blockade with propranolol can improve muscle power, sometimes dramatically, by reducing catecholamine mediated pathways [42]. Thyrotoxic myopathy usually resolves after treatment and became euthyroid [41,43].

Pituitary Dysfunction

Pituitary dysfunction can result with various endocrine disorders such as hypo-hyperthyroidism, gonadal dysfunction, adrenal hypo-hyperfunction, growth retardation and acromegaly or gigantism. Musculoskeletal effects of thyroid and adrenal dysfunction were mentioned above. Patients with acromegaly usually have mild proximal weakness without muscle atrophy. Muscles often appear enlarged. The duration of acromegaly, rather than the serum growth hormone levels, correlates with the degree of myopathy [1]. Serum CK levels generally increased. The average mean action potential duration in the deltoid and rectus femoris muscles in the acromegalics was significantly shorter than in a group of control [44]. Multiple treatment options exist for patients with acromegaly including surgery, radiotherapy, somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists [45].

Parathyroid Disorders

A) Hypoparathyroidism

Hypocalcemia is associated with many musculoskeletal problems such as skeletal hyperostosis, neuromyotonia, myopathy and rhabdomyolysis [46]. Hypocalcemic myopathy is characterized by proximal muscle weakness, hyporeflexia, high levels of serum CK and fatigue [47]. Musculoskeletal symptoms are correlate with severity of hypocalcemia and how quickly the calcium level drops [48]. While tetany, muscle cramps, carpopedal spasm, seizures, and laryngospasm are associated with acute hypocalcemia, non-specific symptoms such as fatigue, irritability and anxiety are associated with chronic hypocalcemia. There is no certain explanation about mechanism of serum CK elevation but in some reports CK is inversely associated with calcium levels [49]. This situation is relevant with disruption the membrane integrity of myocytes, resulting in a leakage of cytoplasmic enzymes such as CK [47]. A recent study retrospectively analyzed the clinical data of nine patients with idiopathic hypoparathyroidism during the years 2006-2010 by Dai et al. and found that mild to moderate muscle cell degeneration were present in almost all patients. The degree of muscle change was related to the duration but not the degree of hypocalcemia [50]. When this is recognized, treatment with calcium and calcitriol relieves symptoms and CK levels return to normal [47,49,51].

B) Hyperparathyroidism

Hyperparathyroidism is the most common reason of hypercalcemia at outpatient [52]. Hyperparathyroidism can cause many musculoskeletal manifestations such as osteitis fibrosa cystica, subperiosteal or articular erosions, chondrocalcinosis, pseudogout, tendon ruptures, myopathy and proximal neuromyopathy [46]. In 2008 due to a retrospective study with fifty one symptomatic hyperparathyroid patient proximal myopathy was the commonest presentation [24/51] [53]. Myopathy resembling polymyositis has been reported in literature but mechanism could not strictly describe [54,55].

In secondary hyperparathyroidism some cases have myopathy because of ischemia by renal failure and arterial calcifications [56]. Myopathy at least some primary hyperparathyroidism has a neurogenic basis and this process result from combination of PTH related muscle breakdown and altered muscle energy metabolism [46]. CK levels are normal or slightly elevated. Electromyographic features may be neurogenic or myopathic. A study with six-teen patients who had primary hyperparathyroidism has shown that Electromyograms of these patients had short-duration, low-amplitude motor unit potentials and distal sensory latencies were normal on the other hands typical myopathic features were absent on the muscle biopsy [57]. There is no need to specific treatment for myopathy, symptoms will resolve several weeks after parathyroidectomy [46,54,57].

Primary Hyperaldosteronism

Primary Hyperaldosteronism [PH] or Conn's disease is a condition resulting in refractory hypertension, hypokalemic paralysis or potassium-losing nephropathy. Tumors and unilateral or bilateral zona glomerulosa hyperplasia can cause this condition [58,59]. Severe muscle weakness is classic manifestation of PH and is usually related to coexistent hypokalemia. Hypokalemic Myopathy [HM] may resemble polymyositis clinically and pathologically and hard to distinguish both disease either clinically or pathologically [60]. Also rhabdomyolysis reported in literature [61,62]. Findings in these patients include muscle pain and weakness, significantly increased creatine kinase, myopathic changes on electromyography and inflammatory cell infiltration, regeneration, necrosis and intracellular vacuoles on muscle biopsy [58]. On the other hand, intracellular vacuoles can be present in inclusion body myositis but at HM, correction of hypocalcemia muscle biopsy return to normal [60]. Treatment of primary hyperaldosteronism related myopathy is that serum potassium normalization and treatment of underlying disease. Surgical excision of tumor is first choice but it is not possible, spironolactone, angiotensin-converting enzyme inhibitors and calcium channel blockers can be alternative treatment [59,61,63].

Osteomalacia

Rickets and osteomalacia have been associated with muscle weakness and hypotonia [64]. Proximal myopathy can effect clinically 13% of patients with osteomalacia [65]. In addition to general weakness, more specific proximal muscle deficits are commonly described, including difficulty rising from a seated position, ascending a flight of stairs, or lifting objects. It is well known that intra -and-extra cellular calcium levels are important for muscle cell contractility [66]. In the reports of myopathy with vitamin D deficiency, many subjects had multiple biochemical abnormalities involving calcium, phosphate and parathyroid hormone levels that can be corrected with vitamin D repletion [65,67]. At this point it is hard to determine that what real reason of myopathy is. In the literature, hypophosphataemia and association of muscle weakness pathophysiology is well known [68]. Experimental studies have also shown skeletal muscles do not contain

vitamin D Receptors[VDR][66,69], which is believed to mediate the all of the known action of vitamin D [70]. There is a conflict about VDR in the literature. In 2013 Girgis et al. reported a review which is about VDR in muscle. They analyzed thirteen study about this issue and stated the conflict [71]. In 2010 Laurie Schubert et al. reported an experimental study which is about vitamin D effects on muscles. Vitamin D treatment significantly improved muscle strength and increased serum phosphorus. Repletion of only phosphorus also increased muscle strength. The improvement of muscle strength correlates well with serum phosphorus levels [64]. This study also support vitamin D has no direct effect on muscles. In most cases of vitamin D deficiency, symptoms and laboratory findings such as ALP elevation hypocalcemia and hypophosphatemia resolve within the therapy with supplemental vitamin D [65,68,72].

Conclusion

Endocrine diseases are generally associated with hormonally-mediated systemic alterations in metabolism. At any time during the course of many endocrinopathies muscle may become affected. The diagnosis of myopathy may be more difficult if it is the first presentation of the endocrinopathy. Although thyroid disorders and cushing disease are well known, literature is limited about endocrine myopathies. While using glucocorticoids and statins as a medication patients must be questioned about muscle weakness in every visit. It is important to understand endocrine myopathy because most cases misdiagnosed and treated like inflammatory myopathy. Also in most cases who has myopathy associated with endocrinopathy, their weakness is improved and serum CK levels normalized by treatment of underlying disease.

References

1. Chawla J (2011) Stepwise approach to myopathy in systemic disease. *Front Neurol* 2: 49.
2. Suresh E, Wimalaratna S (2013) Proximal myopathy: diagnostic approach and initial management. *Postgrad Med J* 89: 470-477.
3. McDonald Cm (2012) Clinical Approach to the Diagnostic Evaluation of Hereditary and Acquired Neuromuscular Diseases. *Physical Medicine And Rehabilitation Clinics Of North America* 23: 495-563.
4. Meola G, Moxley RT 3rd (2004) Myotonic dystrophy type 2 and related myotonic disorders. *J Neurol* 251: 1173-1182.
5. Sharma V, Borah P, Basumatary LJ, Das M, Goswami M, et al. (2014) Myopathies of endocrine disorders: A prospective clinical and biochemical study. *Ann Indian Acad Neurol* 17: 298-302.
6. Valiyil R, Christopher-Stine L (2010) Drug-related myopathies of which the clinician should be aware. *Curr Rheumatol Rep* 12: 213-220.
7. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Lipid-Lowering Drugs And Risk Of Myopathy: A Population-Based Follow-Up Study. *Epidemiology* 12: 565-569.
8. Sathasivam S, Lecky B (2008) Statin induced myopathy. *BMJ* 337: a2286.
9. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH (2003) Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. *Arch Intern Med* 163: 688-692.
10. Dalakas MC (2009) Toxic and drug-induced myopathies. *J Neurol Neurosurg Psychiatry* 80: 832-838.
11. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH (2005) Outcomes in 45 patients with statin-associated myopathy. *Arch Intern Med* 165: 2671-2676.
12. Pereira RM, Freire de Carvalho J (2011) Glucocorticoid-induced myopathy. *Joint Bone Spine* 78: 41-44.
13. Tran M, Elias AN (2003) Severe myopathy and psychosis in a patient with Cushing's disease macroadenoma. *Clin Neurol Neurosurg* 106: 1-4.
14. Guaraldi F, Salvatori R (2012) Cushing syndrome: maybe not so uncommon of an endocrine disease. *J Am Board Fam Med* 25: 199-208.

15. Braunstein PW Jr, DeGirolami U (1981) Experimental corticosteroid myopathy. *Acta Neuropathol* 55: 167-172.
16. Levin OS, Polunina AG, Demyanova MA, Isaev FV (2014) Steroid myopathy in patients with chronic respiratory diseases. *J Neurol Sci* 338: 96-101.
17. Molins A, Alvarez-Sabin J, Montalbán J, Molero J, Alegre J, et al. (1987) Hypopotassemic myopathy caused by topical administration of 9 alpha fluoroprednisolone. *Neurologia* 2: 244-246.
18. Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. *J Endocrinol* 197: 1-10.
19. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP (2013) Glucocorticoid-induced skeletal muscle atrophy. *Int J Biochem Cell Biol* 45: 2163-2172.
20. Kostyo JL, Redmond AF (1966) Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. *Endocrinology* 79: 531-540.
21. Minetto MA, Lanfranco F, Botter A, Motta G, Mengozzi G, et al. (2011) Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease. *European Journal of Endocrinology*. 164: 985-993.
22. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, et al. (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol* 9: 30.
23. Bowyer SL, LaMothe MP, Hollister JR (1985) Steroid myopathy: incidence and detection in a population with asthma. *J Allergy Clin Immunol* 76: 234-242.
24. Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, et al. (1983) Corticosteroid myopathy: a clinical and pathological study. *Clin Endocrinol (Oxf)* 18: 155-166.
25. Iacobone M, Albiger N, Scaroni C, Mantero F, Fassina A, et al. (2008) The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). *World J Surg* 32: 882-889.
26. Wilson D, Jin DL, Wen T, Carmichael JD, Cen S, et al. (2015) Demographic factors, outcomes, and patient access to transsphenoidal surgery for Cushing's disease: analysis of the Nationwide Inpatient Sample from 2002 to 2010. *Neurosurg Focus* 38: E2.
27. Anwar S, Gibofsky A (2010) Musculoskeletal manifestations of thyroid disease. *Rheum Dis Clin North Am* 36: 637-646.
28. Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH (2000) Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. *J Neurol Neurosurg Psychiatry* 68: 750-755.
29. Wood-Allum CA, Shaw PJ (2014) Thyroid disease and the nervous system. *Handb Clin Neurol* 120: 703-735.
30. Scott KR, Simmons Z, Boyer PJ (2002) Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. *Muscle Nerve* 26: 141-144.
31. Madariaga MG (2002) Polymyositis-like syndrome in hypothyroidism: review of cases reported over the past twenty-five years. *Thyroid* 12: 331-336.
32. McKeran RO, Ward P, Slavina G, Paul EA (1979) Central nuclear counts in muscle fibres before and during treatment in hypothyroid myopathy. *J Clin Pathol* 32: 229-233.
33. Somay G, Oflazoğlu B, Us O, Surardamar A (2007) Neuromuscular status of thyroid diseases: a prospective clinical and electrodiagnostic study. *Electromyogr Clin Neurophysiol* 47: 67-78.
34. Kim TJ, Lee HS, Shin JY, Kim DG, Kim SM, et al. (2013) A case of thyrotoxic myopathy with extreme type 2 fiber predominance. *Exp Neurobiol* 22: 232-234.
35. Olson BR, Klein I, Benner R, Burdett R, Trzepacz P, et al. (1991) Hyperthyroid myopathy and the response to treatment. *Thyroid* 1: 137-141.
36. Couillard P, Wijedicks EF (2014) Flaccid quadriplegia due to thyrotoxic myopathy. *Neurocrit Care* 20: 296-297.
37. Boddu NJ, Badireddi S, Straub KD, Schwankhaus J, Jagana R (2013) Acute thyrotoxic bulbar myopathy with encephalopathic behaviour: an uncommon complication of hyperthyroidism. *Case Rep Endocrinol* 2013: 369807.
38. Okada H, Yoshioka K (2009) Thyrotoxicosis complicated with dysphagia. *Intern Med* 48: 1243-1245.
39. Ray S, Kundu S, Goswami M, Maitra S, Talukdar A, et al. (2012) An unusual cause of muscle weakness: a diagnostic challenge for clinicians. *BMJ Case Rep* 2012.
40. Maurya PK, Kalita J, Misra UK (2010) Spectrum of hypokalaemic periodic paralysis in a tertiary care centre in India. *Postgrad Med J* 86: 692-695.
41. Hed R, Kirstein L, Lundmark C (1958) Thyrotoxic myopathy. *J Neurol Neurosurg Psychiatry* 21: 270-278.
42. Pimstone N, Marine N, Pimstone B (1968) Beta-adrenergic blockade in thyrotoxic myopathy. *Lancet* 2: 1219-1220.
43. Papanikolaou N, Perros P (2013) An unusual presenting symptom of graves' disease: myalgia. *Eur Thyroid J* 1: 274-276.
44. Mastaglia FL, Barwich DD, Hall R (1970) Myopathy in acromegaly. *Lancet* 2: 907-909.
45. Del Porto LA, Liubinas SV, Kaye AH (2011) Treatment of persistent and recurrent acromegaly. *J Clin Neurosci* 18: 181-190.
46. Wen HY, Schumacher HR Jr, Zhang LY (2010) Parathyroid disease. *Rheum Dis Clin North Am* 36: 647-664.
47. Hirata D, Nagashima T, Saito S, Okazaki H, Kano S, et al. (2002) Elevated muscle enzymes in a patient with severe hypocalcemia mimicking polymyositis. *Mod Rheumatol* 12: 186-189.
48. Policepatil SM, Caplan RH, Dolan M (2012) Hypocalcemic myopathy secondary to hypoparathyroidism. *WMJ* 111: 173-175.
49. Barber J, Butler RC, Davie MW, Sewry CA (2001) Hypoparathyroidism presenting as myopathy with raised creatine kinase. *Rheumatology (Oxford)* 40: 1417-1418.
50. Dai CL, Sun ZJ, Zhang X, Qiu MC (2012) Elevated muscle enzymes in idiopathic hypoparathyroidism patients. *J Endocrinol Invest* 35: 286-289.
51. Syriou V, Kolitsa A, Pantazi L, Pikazis D (2005) Hypoparathyroidism in a patient presenting with severe myopathy and skin rash. Case report and review of the literature. *Hormones (Athens)* 4: 161-164.
52. Lafferty FW (1991) Differential diagnosis of hypercalcemia. *J Bone Miner Res* 6 Suppl 2: S51-59.
53. Muthukrishnan J, Jha S, Modi KD, Jha R, Kumar J, et al. (2008) Symptomatic primary hyperparathyroidism: a retrospective analysis of fifty one cases from a single centre. *J Assoc Physicians India* 56: 503-507.
54. Kinoshita M, Ikeda K, Iwasaki Y, Saito E, Takamiya K (1989) [A case with polymyositis associated with primary hyperparathyroidism]. *Rinsho Shinkeigaku* 29: 509-512.
55. Kuntz JL, Sutter B, Salamito D, Bloch JG, Schneider P, et al. (1988) [Hyperparathyroidism and polymyositis]. *Rev Rhum Mal Osteoartic* 55: 287-290.
56. Stavros K, Motiwala R, Zhou L, Seidiu F, Shin S (2014) Calciphylaxis in a dialysis patient diagnosed by muscle biopsy. *Journal of Clinical Neuromuscular Disease*. 15: 108-111.
57. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, et al. (1974) Neuromuscular disease in primary hyperparathyroidism. *Ann Intern Med* 80: 182-193.
58. Tang YC, Wang SK, Yuan WL (2011) Primary aldosteronism simulating polymyositis. *J Rheumatol* 38: 1529-1533.
59. Kotsaftis P, Savopoulos C, Agapakis D, Ntaios G, Tzioufa V, et al. (2009) Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism in an elderly patient with unilateral adrenal hyperplasia: a case report. *Cases Journal* 2: 6813.
60. Kaşifoğlu T, Korkmaz C, Paşaoğlu O (2005) Conn's syndrome (primary hyperaldosteronism) simulating polymyositis. *Rheumatol Int* 25: 133-134.
61. Tsai WT, Chen YL, Yang WS, Lin HD, Chien CC, et al. (2012) Primary aldosteronism associated with severe hypokalemic rhabdomyolysis. *Hormones (Athens)* 11: 505-506.
62. Wen Z, Chuanwei L, Chunyu Z, Hui H, Weimin L (2013) Rhabdomyolysis presenting with severe hypokalemia in hypertensive patients: a case series. *BMC Res Notes* 6: 155.
63. Ahlawat SK, Sachdev A (1999) Hypokalaemic paralysis. *Postgrad Med J* 75: 193-197.

64. Schubert L, DeLuca HF (2010) Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. *Arch Biochem Biophys* 500: 157-161.
65. Thabit H, Barry M, Sreenan S, Smith D (2011) Proximal myopathy in lacto-vegetarian Asian patients responding to Vitamin D and calcium supplement therapy - two case reports and review of the literature. *Journal of Medical Case Reports* 5: 178.
66. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano K, et al. (1997) Calcium movements, distribution, and functions in smooth muscle. *Pharmacol Rev* 49: 157-230.
67. Fluss J, Kern I, de Coulon G, Gonzalez E, Chehade H (2014) Vitamin D deficiency: a forgotten treatable cause of motor delay and proximal myopathy. *Brain Dev* 36: 84-87.
68. Ritz E, Haxsen V, Zeier M (2003) Disorders of phosphate metabolism pathomechanisms and management of hypophosphataemic disorders. *Best Practice and Research Clinical Endocrinology and Metabolism*. 17(4): 547-558.
69. Sandgren ME, Brönnegård M, DeLuca HF (1991) Tissue distribution of the 25-dihydroxyvitamin D3 receptor in the male rat. *Biochem Biophys Res Commun* 181: 611-616.
70. Jones G, Strugnell SA, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. *Physiol Rev* 78: 1193-1231.
71. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE (2013) The roles of vitamin D in skeletal muscle: form, function, and metabolism. *Endocr Rev* 34: 33-83.
72. Fabbriani G, Pirro M, Leli C, Cecchetti A, Callarelli L, et al. (2010) Diffuse musculoskeletal pain and proximal myopathy: do not forget hypovitaminosis D. *J Clin Rheumatol* 16: 34-37.

Citation: Yeter HH (2015) Endocrine Myopathies: Clinical Review. *Endocrinol Metab Synd* 4: 178. doi:10.4172/2161-1017.1000178

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 350 Open Access Journals
- 30,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.editorialmanager.com/biochem>

